ArticleCureus2025
Evaluating Prostate-Specific Antigen (PSA) Density Thresholds for Detecting Clinically Significant Prostate Cancer in Prostate Imaging Reporting and Data System (PI-RADS) 3 Lesions: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Value of PSA density in PI-RADS 3 lesions: a single-center retrospective observational study.International urology and nephrology · 2026Observational
- PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Prostate cancer is one of the most common cancers in the world. Equivocal prostate magnetic resonance imaging (MRI) findings (Prostate Imaging Reporting and Data System [PI-RADS] 3) remain a diagnostic challenge. The use of prostate-specific antigen density (PSAD) has been suggested to help risk-stratify this cohort of patients to help guide the decision to biopsy. This study aimed to evaluate the diagnostic performance of PSAD across multiple cut-offs in detecting clinically significant prostate cancer (csPCa) in patients with PI-RADS 3 lesions. Methods A retrospective audit of 194 men with PI-RADS 3 lesions on multiparametric magnetic resonance imaging (mpMRI) who underwent prostate biopsy was performed. Age, prostate-specific antigen (PSA), prostate volume, and PSAD were collected. Receiver operating characteristic (ROC) analysis was used to assess model accuracy. Univariate and multivariate logistic regression were performed to identify significant predictors of csPCa. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated at PSAD thresholds of 0.10, 0.15, and 0.20 ng/mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.